Suppression of tumour development by substances derived from the diet - Mechanisms and clinical implications

British Journal of Clinical Pharmacology

Volumn 45, Issue 1, 1998, Pages 1-12

  Gescher, Andreas ^a   Pastorino, Ugo ^b   Plummer, Simon M ^a   Manson, Margaret M ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Cancer chemoprevention; Curcumin; Genistein; Mechanisms; Retinoids

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; BETA CAROTENE; CURCUMIN; GENISTEIN; ISOTRETINOIN; NONSTEROID ANTIINFLAMMATORY AGENT; RESVERATROL; RETINOIC ACID; RETINOID; SULINDAC; TAMOXIFEN;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BREAST CANCER; CANCER; CANCER PREVENTION; CLINICAL TRIAL; CONJUNCTIVITIS; DIET SUPPLEMENTATION; DRUG MECHANISM; DRY SKIN; HUMAN; HYPERTRIGLYCERIDEMIA; LUNG CANCER; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; CHEMOPREVENTION; CLINICAL TRIALS; CURCUMIN; DIET; GENISTEIN; HUMANS; NEOPLASMS; TRETINOIN;

EID: 0031930629     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00640.x     Document Type: Review

References (99)

1. Weinstein IB. Cancer prevention: recent progress and future opportunities. Cancer Res 1991; 51: 5080s-5085s.
2. Wattenberg LW. Chemoprophylaxis of carcinogenesis: A review. Cancer Res. 1966; 26: 1520-1526.
3. Ruddon RW. Cancer Biology. Oxford University Press, 1995.
4. Wattenberg LW. Chemoprevention of cancer. Cancer Res 1985; 45: 1-8.
5. Kelloff GJ, Boone CW, Crowell JA, et al. Chemopreventive drug development: perspectives and progress. Cancer Epidemiol Biomarkers Prev 1994; 3: 85-98.
6. Greenwald P. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials. J Cell Biochem 1996; 25S: 29-36.
7. The alpha-tocopherol, beta-carotene cancer prevention study group. The effects of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-1035.
8. Omenn GS, Goodman GE, Thornquist MO, et al. Effects of a combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-1155.
9. Albanes D, Heinonen OP, Taylor PR, et al. Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study: effects of base line characteristics and study compliance. J Natl Cancer Inst 1996; 88: 1560-1570.
10. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and retinol Efficacy Trial. J Natl Cancer Inst 1996; 88: 1550-1559.
11. Lee JS; Lippman SM; Hong WK, et al. Determination of biomarkers for intermediate end points in chemoprevention trials. Cancer Res 1992, 52: 2707s-2710s.
12. Lotan R. Retinoids in cancer chemoprevention. FASEB J 1996; 10: 1031-1039.
13. Hong WK, Itri LM. Retinoids and human cancer. In The retinoids, eds Sporn MB, Roberts AB, Goodman DS. Raven Press, New York, 1994; 597-658.
14. Moon RC, Mehta RG, Rao KJVN. Retinoids and cancer in experimental animals. In The retinoids, eds Sporn MB, Roberts AB, Goodman DS. Raven Press, New York, 1994; 573-595.
15. Goodman DS. Vitamin A and retinoids in health and disease. N Engl J Med 1984; 310: 1023-1031.
16. Dowling JE, Wald J. The biological function of vitamin A acid. Proc Natl Acad Sci USA 1960; 46: 587-608.
17. Thompson JN, Howell JM, Pitt GAJ. Vitamin A and reproduction in rats. Proc R Soc Lond 1964; 159: 510-535.
18. Wolbach SB, Howe PR. Tissue changes following deprivation of fat soluble A vitamin. J Exp Med 1925; 42: 753-777.
19. Saffiotti U, Montesano R, Sellakumar AR, Bork SA. Experimental cancer of the lung. Inhibition by vitamin A of the induction of tracheobronchial metaplasia and squamous cell tumor. Cancer 1967; 20: 857-864.
20. Peck GL, DiGiovanna JJ. Synthetic retinoids in dermatology. In The retinoids, eds Sporn MB, Roberts AB, Goodman DS. Raven Press, New York, 1994; 631-658.
21. Morriss-Kay G. Retinoids and embryos. In Retinoids in Oncology, eds Degos L, Parkinson DR. Springer, Berlin, Heidelberg, New York, 1995; 43-54.
22. Messina MJ, Persky V, Detchell KD, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994; 21: 113-131.
23. Coward L, Barnes NC, Setchell KDR, Barnes S. Genistein and daidzein, and their beta-glycoside conjugates: antitumor isoflavones in soybean foods of the American and Asian diets. J Agric Food Sci 1993; 41: 1961-1967.
24. Jones AE, Price KR, Fenwick GR. Development and application of a high-performance liquid chromatographic method for the analysis of phytoestrogens. J Sci Food Agric 1989; 46: 357-364.
25. Adlercreutz H, Mazur W. Phyto-oestrogens and Western diseases. Ann Med 1997; 29: 95-120.
26. Barnes S. Effect of genistein on in vitro and in vivo models of cancer. J Nutr 1995; 125: 777s-783s.
27. Lamartiniere CA, Moore JB, Brown NM, Thompson R, Hardin MY, Barnes S. Genistein suppresses mammary cancer in rats. Carcinogenesis 1995; 16: 2833-2840.
28. Govindarajan VS. Turmeric chemistry, technology and quality. CRC Rev Food Sci Nutr 1980; 12: 199-301.
29. Stoner GD, Mukhtar H. Polyphenols as cancer chemopreventive agents. J Cell Biochem 1995; 22: 169-180.
30. Huang MT, Smart RC, Wong CQ, Conney AH. Inhibitory effect of curcumin, chlorogenic acid and fenilic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 1988; 48: 5941-5946.
31. Nagabbushan M, Bhide SV. Curcumin as an inhibitor of cancer. J Am Coll Nutr 1992; 11: 192-198.
32. Mehta RG, Moon RC. Characterization of effective chemopreventive agents in mammary gland in vitro using an initiation-promotion protocol. Anticancer Res 1991; 11: 593-596.
33. Rao CV, Simi B, Reddy BS. Inhibitory effect by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tysosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis 1993; 14: 2219-2225.
34. Kensler TW, Trush MA, Guyton KZ. Free radicals as targets for cancer chemoprevention: Prospects and problems. In Cellular and Molecular Targets for Chemoprevention, eds Steel VE, Stoner GDM, Boon CW, Kelloff GJ. CRC Press, Boca Raton, FL, 1992; 173-191.
35. Irani K, Xia Y, Zweier JL, et al. Mitogenic signaling mediated by oxidants in ras-transformed fibroblasts. Science 1997; 275: 1649-1652.
36. Hartman PE, Shankel DM. Antimutagens and anticarcinogens: A survey ot putative interceptor molecules. Environ Mol Mutagen 1990; 15: 145-182.
37. Twentyman PR, Fox NE, White DJ. Cyclosporin A and its analogues as modifiers ot adriamycin and vincristine resistance in multi-drag resistant human lung cancer cell line. Br J Cancer 1987; 56: 55-57.
38. Marnett LJ. Asprin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575-5589.
39. Zenser TV, Davis BB. Arachidonic acid metablolism. In Cellular and Molecular Targets for Chemoprevention, eds Steel VE, Stoner GDM, Boon CW, Kelloff GJ. CRC Press, Boca Raton, FL, 1992; 225-243.
40. Plummer, S.M., Hall, M., Faux, S.P. Oxygenation and genotoxicity of fecapentaene-12 are potentiated by prostaglandin H synthase. Carcinogenesis 1995; 16: 1023-1028.
41. Smith WL. The eicosanoids and their biochemical mechanisms of action. Biochem J 1989; 259, 315-324.
42. Earnest DL, Hixson LJ, Finley PR, et al. Arachidonic acid cascade inhibitors in chemoprevention of human colon cancer: Preliminary studies. In Cancer Chemoprevention, eds Wattenberg L, Lipkin M, Boone OW, Kelloff, GJ. CRC Press, Boca Raton, FL, 1992; 165-180.
43. Ristimaki A, Honkanen N, Jankala H, Sipponen P. Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 1276-1280.
44. Parrett ML, Harns RE, Joarder FS, Ross MS, Clausen KP, Robertson FM. Cyclooxygenase gene expression in human breast cancer. Int J Oncol 1997; 10: 530-507.
45. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in APC knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87; 803-809.
46. Tsujii M, Dubois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
47. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322-1327.
48. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996; 56: 2556-2560.
49. Holloway K, Plummer S. Induction of COX2 mRNA and NFkB DNA binding activity by TNF-alpha and fecapentaene-12 is inhibited by curcumin. Eur J Cancer Prev (in press).
50. Mestre JR, Subbaramaiah K, Sacks PG, et al. Retinoids suppress phorbol ester-mediated induction of cyclooxygenase-2. Cancer Res 1997; 57: 1081-1085.
51. Tsai MJ, O'Malley BW. Molecular mechanisms of actions of steroid/thyroid receptor super-family members. Ann Rev Biochem 1994; 63: 451-486.
52. Gronemeyer H, Benhamou B, Berry M, et al. Mechanisms of antihormone action. J Steroid Biochem Mol Biol 1992; 41: 217-221.
53. Jordan VC. The strategic use of antiestrogens to control the development and growth of breast cancer. Cancer 1992; 70: 977-982.
54. Martin PM, Horwitz KB, Ryan DS, McGuire WI. Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology 1978; 103: 1860-1867.
55. Roberts AB, Sporn, MB. Tranforming growth factor β. Adv Cancer Res 1988; 51: 107-145.
56. Sibrestein GB, Daniel CW. Reversible inhibition of mammary gland growth by tranforming growth factor-β. Science 1987; 237: 291-293.
57. Sporn MB, Roberts AB, Glick AB, Luckert PH, Pollard M. Interactions of retinoids and transforming growth factor β in the chemoprevention of cancer. In Control of growth factors and prevention of cancer, ed Sporn MB. Springer Verlag, New York, 1992; 37-46.
58. Russell WE, Coffey, RJ Jr, Ouellette AJ, Moses HL. Type β transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. Proc Natl Acad Sci USA 1988; 85: 5126-5130.
59. Glick AB, McCune BK, Abdulkarem N, et al. Complex regulation of TGFβ expression by retinoic acid in the vitamin A-deficient rat. Development 1991; 111: 1081-1086.
60. Kumar R, Shoemaker AR, Verma AK. Retinoic acid nuclear receptors and tumor promotion: decreased expression of retinoic acid nuclear receptors by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate. Carcinogenesis 1994; 15: 701-705.
61. Xu XC, Sozzi G, Lee JS, et al. Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: Implications for lung cancer development. J Natl Cancer Inst 1997; 89: 624-629.
62. Li JJ, Dong ZG, Dawson MI, Colburn NH. Inhibition of tumor promotor-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element. Cancer Res 1996; 56: 483-489.
63. Suganuma M, Okabe S, Suoka E, et al. A new process of cancer prevention through inhibition of tumor necrosis factor alpha expression. Cancer Res 1996; 56: 3711-3715.
64. Cooper GM. Oncogenes and growth factors. In Oncogenes, chapter 11, Jones and Bartlett Publishers, Boston, 1990: 163-173.
65. Powis G. Signalling pathways as targets for anticancer drug development. Pharmacol Ther 1994; 62: 57-95.
66. Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesion during head and neck tumorigenesis. Cancer Res 1994; 54: 3153-3159.
67. Levitzky A. Signal-transduction therapy. A novel approach to disease management. Eur J Biochem 1994; 226: 1-13.
68. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptors in human cancers. Br Med Bull 1991; 47: 87-98.
69. Lee DC, Fenton SE, Berkowitz EA, Hissong MA. Transforming growth factor alpha: expression regulation, and biological activities. Pharmacol Rev 1995; 47: 51-85.
70. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Onol Hematol 1995; 19: 183-232.
71. Kumar V, Bustin SA, McKay IA. Transforming growth factor alpha. Cell Biol Int 1995; 19: 373-388.
72. Boonstra J, Rijken P, Humbel B, Cremers F, Verkleij A, van Bergen-Henegouwen P. The epidermal growth factor. Cell Biol Int 1995; 19: 413-430.
73. Briscoe J, Guschin D, Muller M. Just another signalling pathway. Curr Biol 1994; 4: 1033-1035.
74. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987; 262: 5592-5595.
75. Barnes S. Effect of genistein on in vitro and in vivo models of cancer. J Nutr 1995; 125: 777s-783s.
76. Peterson TG, Barnes S. Isoflavones inhibit the growth of human prostate cancer cell lines without inhibiting epidermal growth factor receptor autophosphorylation. Prostate 1993; 22: 335-345.
77. Peterson TG, Barnes S. Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. Cell Growth Diff 1996; 7: 1345-1351.
78. Kikkawa U, Nishizuka Y. The role of protein kinase C in transmembrane signalling. Ann Rev Cell Biol 1986; 2: 149-178.
79. Liu JY, Lin SJ, Lin JK. Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoylphorbol-13-acetate in NIH 3T3 cells. Carcinogenesis 1993; 14: 857-861.
80. Korutla L, Cheung JY, Mendelsohn J, Kumar R. Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. Carcinogenesis 1995; 16: 1741-1745.
81. Tseng CP, Verma AK. Inhibition of 12-O-tetradecanoyl-13-phorbol-13-acetate-induced ornithine decarboxylase activity by genistein, a tyrosine kinase inhibitor. Mol Pharmacol 1996; 50: 249-257.
82. Weinstein IB. Strategies for inhibiting multistage carcinogenesis based on signal transduction pathways. Mutat Res 1988; 202: 413-420.
83. Zarbl H, Sukumar S, Arther AV, Martin-Zanca, D, Barbacid M. Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature 1985; 315: 382-385.
84. Haag JD, Lindstrom MJ, Gould MN. Limonene-induced regression of mammary carcinomas. Cancer Res 1992; 52: 4021-4026.
85. Haag JD, Crowell PL, Gould MN. Enhanced inhibition of protein isoprenylation and tumor growth by perillyl alcohol, an hydroxylated analog of D-limonene. Proc Am Assoc Cancer Res 1992; 33: 3135.
86. Crowell PL, Chang RR, Ren Z, Elson CE, Gould MN. Selective inhibition of isoprenylation of 21-26-KDa proteins by the anticarcinogen d-limonene and its metabolites. J Biol Chem 1991; 266: 17679-17685.
87. Sebti SM, Tkalcevic GT, Jani JP. Lovastatin, a cholestrol biostynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. Cancer Commun 1991; 3: 141-147.
88. Nolan RD, Danilowicz RM, Eling TE. Role of arachidonic acid metabolism in the mitogenic response of BALB/c 3T3 fibroblasts to epidermal growth factor. Mol Pharmacol 1988; 33: 650-656.
89. Handler JA, Danilowicz RM, Eling TE. Mitogenic signaling by epidermal growth factor (EGF), but not platelet-derived growth factor, requires arachidomc acid metabolism in BALB/c3T3 cells. J Biol Chem 1990; 265: 3669-3673.
90. Huang TS, Lee SC, Lin JK. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci USA 1991; 88: 5292-5296.
91. Schultze-Mosgau M, Gant TW, Gescher A. Regulation of c-fos transcription by chemopreventive isoflavonoids and lignans in MDA-MB-468 breast cancer cells. Int J Cancer (in press).
92. Pezzuto JM. Plant-derived anticancer agents. Biochem Pharmacol 1997; 53: 121-133.
93. Sharma S, Stutzman JD, Kelloff GJ, Steele VE. Screening of potential chemopreventive agents using biochemical markers of carcinogenesis. Cancer Res 1994; 54: 5848-5855.
94. Gerhäuser C, Mar W, Lee SK, et al. Rotenoids mediate potent cancer chemopreventive activity through transcnptional regulation of ornithine decarboxylase. Nature Med 1995; 1: 260-266.
95. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218-220.
96. Goodman GE. The clinical evaluation of cancer chemoprevention agents: defining and contrasting phase I, II, and II objectives. Cancer Res 1992; 52: 2752s-2757s.
97. J Cell Biol 1996; Suppl. 25, 1-206.
98. Soto AM, Fernandez MF, Luizzi MF, Oles Karasko AS, Sonnenschein C. Developing a marker of exposure to xenoestrogen mixtures in human serum. Environ Health Perspect 1997; 105: 647-654.
99. Macara IG. Oncogenes and cellular signal transduction. Physiol Rev 1989; 69: 797-820.